Form 4: Senseonics Director Steven Edelman Receives Equity Grant
Statement of Changes in Beneficial Ownership
Director Steven Edelman was granted 9,852 restricted stock units and 13,574 stock options as part of the company's non-employee director compensation policy.
Summary
- Director Steven Edelman acquired 9,852 restricted stock units (RSUs) on May 20, 2026.
- The director also received a grant of 13,574 stock options with an exercise price of $5.71.
- These grants were issued under the Senseonics Holdings, Inc. non-employee director compensation policy.
- Following these transactions, the director's total beneficial ownership of common stock is 88,681 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.
Positives
- Alignment of director interests with shareholders through equity-based compensation.
- Standardized compensation structure for non-employee directors.
Negatives
- Issuance of equity results in minor dilution to existing shareholders.
Risks
- Vesting is subject to the director's continuous service through the earlier of the one-year anniversary or the next annual stockholders meeting.
Future Outlook
The equity grants vest in full on the earlier of the one-year anniversary of the grant date or the next annual stockholders meeting, contingent upon continued service.
Industry Context
StockSavvy.ai notes that equity-based compensation for board members is a standard corporate governance practice in the medical technology sector to ensure long-term alignment with company performance.
Comparison to Industry Standards
- The grant structure is consistent with typical non-employee director compensation packages for small-cap medical device companies.
- Vesting schedules align with standard one-year cliff or annual meeting cycles common in the industry.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation | Grant of equity under the established non-employee director compensation policy. | 05/20/2026 | Standard alignment of director incentives. |
Stakeholder Impact
- Minor dilution for existing shareholders due to the issuance of new equity.
Next Steps
- Vesting of RSUs and options on the earlier of May 20, 2027, or the date of the next annual stockholders meeting.
Key Dates
| Date | Description |
|---|---|
| 05/20/2026 | Date of the equity grant transaction. |
| 05/19/2036 | Expiration date of the granted stock options. |
Keywords
Senseonics, SENS, Director Compensation, Form 4, Equity Grant, Insider Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.